vs
STANDARD BIOTOOLS INC.（LAB）与SB FINANCIAL GROUP, INC.（SBFG）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是SB FINANCIAL GROUP, INC.的1.2倍（$19.6M vs $16.4M），SB FINANCIAL GROUP, INC.净利率更高（23.9% vs -177.4%，领先201.3%），SB FINANCIAL GROUP, INC.同比增速更快（6.3% vs -11.5%），SB FINANCIAL GROUP, INC.自由现金流更多（$21.4M vs $-23.1M），过去两年SB FINANCIAL GROUP, INC.的营收复合增速更高（11.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
SB金融集团是总部位于美国的金融控股企业，主营个人与商业银行业务，提供存款账户、按揭及消费贷款、小微企业融资、财富管理等服务，核心客群覆盖美国多区域的零售用户与中小型企业。
LAB vs SBFG — 直观对比
营收规模更大
LAB
是对方的1.2倍
$16.4M
营收增速更快
SBFG
高出17.7%
-11.5%
净利率更高
SBFG
高出201.3%
-177.4%
自由现金流更多
SBFG
多$44.5M
$-23.1M
两年增速更快
SBFG
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $16.4M |
| 净利润 | $-34.7M | $3.9M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 30.3% |
| 净利率 | -177.4% | 23.9% |
| 营收同比 | -11.5% | 6.3% |
| 净利润同比 | -28.8% | 7.8% |
| 每股收益（稀释后） | $-0.09 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSBFG
| Q4 25 | — | $16.4M | ||
| Q3 25 | $19.6M | $16.6M | ||
| Q2 25 | $21.8M | $17.2M | ||
| Q1 25 | $40.8M | $15.4M | ||
| Q4 24 | — | $15.5M | ||
| Q3 24 | $22.1M | $14.3M | ||
| Q2 24 | $22.5M | $14.0M | ||
| Q1 24 | $45.5M | $13.1M |
净利润LABSBFG
| Q4 25 | — | $3.9M | ||
| Q3 25 | $-34.7M | $4.0M | ||
| Q2 25 | $-33.5M | $3.9M | ||
| Q1 25 | $-26.0M | $2.2M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $-26.9M | $2.4M | ||
| Q2 24 | $-45.7M | $3.1M | ||
| Q1 24 | $-32.2M | $2.4M |
毛利率LABSBFG
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABSBFG
| Q4 25 | — | 30.3% | ||
| Q3 25 | -168.5% | 29.9% | ||
| Q2 25 | -118.1% | 27.5% | ||
| Q1 25 | -80.8% | 16.8% | ||
| Q4 24 | — | 29.3% | ||
| Q3 24 | -120.9% | 21.7% | ||
| Q2 24 | -134.5% | 24.0% | ||
| Q1 24 | -132.2% | 21.7% |
净利率LABSBFG
| Q4 25 | — | 23.9% | ||
| Q3 25 | -177.4% | 24.4% | ||
| Q2 25 | -153.7% | 22.4% | ||
| Q1 25 | -63.8% | 14.0% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | -122.0% | 16.5% | ||
| Q2 24 | -203.3% | 22.2% | ||
| Q1 24 | -70.6% | 18.0% |
每股收益（稀释后）LABSBFG
| Q4 25 | — | $0.62 | ||
| Q3 25 | $-0.09 | $0.64 | ||
| Q2 25 | $-0.09 | $0.60 | ||
| Q1 25 | $-0.07 | $0.33 | ||
| Q4 24 | — | $0.55 | ||
| Q3 24 | $-0.07 | $0.35 | ||
| Q2 24 | $-0.12 | $0.47 | ||
| Q1 24 | $-0.27 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $141.2M |
| 总资产 | $539.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSBFG
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABSBFG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | $55.2M | $19.7M | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSBFG
| Q4 25 | — | $141.2M | ||
| Q3 25 | $399.7M | $136.9M | ||
| Q2 25 | $424.5M | $133.6M | ||
| Q1 25 | $454.6M | $131.5M | ||
| Q4 24 | — | $127.5M | ||
| Q3 24 | $489.3M | $132.8M | ||
| Q2 24 | $510.3M | $125.5M | ||
| Q1 24 | $577.3M | $123.7M |
总资产LABSBFG
| Q4 25 | — | $1.5B | ||
| Q3 25 | $539.6M | $1.5B | ||
| Q2 25 | $557.0M | $1.5B | ||
| Q1 25 | $579.6M | $1.5B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $681.5M | $1.4B | ||
| Q2 24 | $708.7M | — | ||
| Q1 24 | $777.7M | — |
负债/权益比LABSBFG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | 0.11× | 0.15× | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $24.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $21.4M |
| 自由现金流率自由现金流/营收 | -118.1% | 130.6% |
| 资本支出强度资本支出/营收 | 4.5% | 15.8% |
| 现金转化率经营现金流/净利润 | — | 6.14× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $35.3M |
8季度趋势，按日历期对齐
经营现金流LABSBFG
| Q4 25 | — | $24.0M | ||
| Q3 25 | $-22.2M | $12.7M | ||
| Q2 25 | $-20.7M | $-3.6M | ||
| Q1 25 | $-30.3M | $6.7M | ||
| Q4 24 | — | $9.5M | ||
| Q3 24 | $-27.9M | $3.6M | ||
| Q2 24 | $-39.0M | $-434.0K | ||
| Q1 24 | $-62.5M | $308.0K |
自由现金流LABSBFG
| Q4 25 | — | $21.4M | ||
| Q3 25 | $-23.1M | $12.2M | ||
| Q2 25 | $-22.6M | $-4.2M | ||
| Q1 25 | $-35.3M | $5.8M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | $-30.1M | $3.2M | ||
| Q2 24 | $-41.0M | $-833.0K | ||
| Q1 24 | $-63.3M | $149.0K |
自由现金流率LABSBFG
| Q4 25 | — | 130.6% | ||
| Q3 25 | -118.1% | 73.8% | ||
| Q2 25 | -103.6% | -24.2% | ||
| Q1 25 | -86.6% | 37.6% | ||
| Q4 24 | — | 53.2% | ||
| Q3 24 | -136.4% | 22.6% | ||
| Q2 24 | -182.2% | -5.9% | ||
| Q1 24 | -138.9% | 1.1% |
资本支出强度LABSBFG
| Q4 25 | — | 15.8% | ||
| Q3 25 | 4.5% | 2.7% | ||
| Q2 25 | 8.7% | 3.1% | ||
| Q1 25 | 12.4% | 6.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 10.2% | 2.7% | ||
| Q2 24 | 8.6% | 2.8% | ||
| Q1 24 | 1.7% | 1.2% |
现金转化率LABSBFG
| Q4 25 | — | 6.14× | ||
| Q3 25 | — | 3.14× | ||
| Q2 25 | — | -0.94× | ||
| Q1 25 | — | 3.11× | ||
| Q4 24 | — | 2.60× | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | -0.14× | ||
| Q1 24 | — | 0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SBFG
暂无分部数据
